Cartesian Therapeutics (RNAC) Total Debt (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Total Debt for 9 consecutive years, with $24.0 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Total Debt fell 7.32% year-over-year to $24.0 million; the TTM figure through Jun 2023 stood at $24.0 million (down 7.32% YoY), while the FY2022 annual figure was $26.3 million, up 2.45% from the prior year.
• Total Debt fell to $24.0 million in Q2 2023 per RNAC's latest filing, from $26.4 million in the prior quarter.
• Across five years, Total Debt topped out at $26.4 million in Q1 2023 and bottomed at $14.8 million in Q2 2020.
• Historically, Total Debt has averaged $23.3 million across 5 years, with a median of $24.9 million in 2020.
• Annual changes were most pronounced in 2020 — Total Debt plunged 31.16% — and 2021, when it soared 70.04%.
• Cartesian Therapeutics' Total Debt stood at $18.9 million in 2019, then soared by 31.15% to $24.8 million in 2020, then gained by 3.39% to $25.6 million in 2021, then climbed by 2.45% to $26.3 million in 2022, then fell by 8.53% to $24.0 million in 2023.
• Business Quant data shows RNAC's Total Debt at $24.0 million in Q2 2023, $26.4 million in Q1 2023, and $26.3 million in Q4 2022.